Vitaimuno - Company finances
|
EUR
|
2023
From: 2023-01-16
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 15,904 | 26,506 | 21,255 |
| Profit before tax | 700 | 2,381 | 195 |
| Net profit | 550 | 2,024 | 166 |
| Equity | 3,049 | 5,073 | 5,269 |
| Liabilities | 5,125 | 2,850 | 955 |
| Non-current assets | 1,144 | 671 | 1,107 |
| Current assets | 7,030 | 7,252 | 5,117 |
| Total assets | 8,174 | 7,923 | 6,224 |
|
Taxes paid
|
|||
| STI taxes | 2,501 | 6,093 | 3,984 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +66.7% | -19.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 6.7% | 25.5% | 2.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 18.0% | 39.9% | 3.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.5% | 7.6% | 0.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.4% | 9.0% | 0.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.7 | 0.6 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vitaimuno - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-03 | 2026-06-30 | 80.48 |
| 2026-04-01 | 2026-04-30 | 80.48 |
Vitaimuno - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-10-30 | 2025-11-24 | 0.36 |
| 2025-09-28 | 2025-10-24 | 0.36 |
| 2025-08-28 | 2025-09-23 | 0.36 |
| 2025-07-28 | 2025-08-25 | 0.36 |
| 2025-07-10 | 2025-07-23 | 0.1 |
| 2025-07-03 | 2025-07-09 | 59.88 |
| 2025-07-01 | 2025-07-02 | 211.01 |
| 2025-06-29 | 2025-06-30 | 210.75 |
| 2025-06-28 | 2025-06-28 | 269.75 |
| 2025-06-27 | 2025-06-27 | 210.73 |
| 2025-06-19 | 2025-06-26 | 210.25 |
| 2024-12-03 | 2024-12-03 | 608.16 |
| 2024-11-28 | 2024-12-02 | 607.36 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vitaimuno, MB (company code 306222199) is a Small partnership engaged in the retail sale of pharmaceutical products. In 2025, the latest financial year, the company generated revenue of €21.3K and net profit of €166, resulting in a profit margin of 0.8%. This was weaker than 2024, when revenue reached €26.5K and net profit was €2.0K, but still above 2023, when revenue was €15.9K and net profit €550. Over the 2023–2025 period, revenue increased overall, although it declined in 2025 after the stronger 2024 result. The balance sheet also remained small and stable in absolute terms: total assets decreased from €8.2K in 2023 to €6.2K in 2025, while equity increased slightly from €3.0K to €5.3K and liabilities fell from €5.1K to €955. In 2025, equity accounted for 84.7% of assets and debt-to-equity stood at 0.18. Return on equity was 3.1%, return on assets 2.7%, and asset turnover 3.42x.